Luvo Health vs Ro
Two GLP-1 desks, one scoreboard. We put Luvo Health and Ro head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 79 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Luvo Health a bad call — it's best for readers who want to see every term length and its exact price before choosing — and who are genuinely willing to prepay a longer term (up to a year) to bring the per-week cost down, rather than shopping for the lowest month-to-month rate. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Luvo Health | Ro | |
|---|---|---|
| Brief Score | 79/100 (C) | 87/100 (B+) |
| Semaglutide | $249/4-wk injection or $279/4-wk tablets — as low as $45/wk (injection), but only on a prepaid 52-wk term | Not disclosed |
| Tirzepatide | $339/4-wk term — as low as $67/wk, but only on a prepaid 52-wk term | Not disclosed |
| Coverage | Not disclosed | Multi-state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Luvo Health: 4-week entry prices unchanged from our last reading ($249 semaglutide injection / $339 tirzepatide), but this pass confirmed the full term ladder: both molecules get progressively cheaper per week on 12-, 24- and 52-week prepaid terms, down to $45/wk and $67/wk respectively — real savings, in exchange for a real lump-sum commitment.
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.